Oculus Innovative Sciences Netherlands B.V. (a wholly owned subsidiary of Oculus Innovative Sciences, Inc.) was founded at the end of 2003. This European entity directs the marketing, manufacturing and distribution of Dermacyn^® products in Europe, Africa and Eastern markets. The facility is located in Sittard (in the southeastern part of the Netherlands); strategically located for access to our markets. The Sittard region provides an excellent business infrastructure and a regional government with a genuine appreciation of life sciences technologies.

The European organization is focused on generating market awareness of the wound management capabilities of the disruptive Microcyn^®-Technology. Dermacyn^® Wound Care is a super-oxidized solution for treating acute and chronic wounds (e.g. diabetic foot ulcers and burns). The combination of excellent performance (broadly applicable within a comprehensive wound treatment); unparalleled safety for patient, medical practitioner and environment; and a ready-to-use, extended-shelf-life formula makes Dermacyn^® Wound Care a clear revolution. The application has received approval according to the European Medical Devices Directive (93/42/EEC). This CE-certification was obtained in November 2004.

Oculus Innovative Sciences Netherlands has adopted a market acquisition strategy which employs a regionally segmented distributor network. Having launched Dermacyn^® Wound Care late 2004, we are currently expanding this network in the European, African and Eastern territories.

For more information please contact:

Oculus Innovative Sciences Netherlands B.V.
P.O. Box 5056
6130 PB Sittard
The Netherlands

Customer Service Europe
Telephone: +31- (46) - 4572 300
FAX: +31- (46) - 4572 399
Email: Info.europe@oculusis.com